Aurinia Pharmaceuticals Inc (AUPH) Expected to Announce Earnings of -$0.13 Per Share
Brokerages expect Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) to announce ($0.13) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Aurinia Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.13) and the highest is ($0.12). Aurinia Pharmaceuticals reported earnings per share of ($0.19) in the same quarter last year, which suggests a positive year over year growth rate of 31.6%. The company is expected to report its next quarterly earnings report on Friday, November 3rd.
According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full year earnings of ($0.99) per share for the current fiscal year, with EPS estimates ranging from ($1.05) to ($0.89). For the next year, analysts forecast that the company will report earnings of ($0.58) per share, with EPS estimates ranging from ($0.72) to ($0.43). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.10. The firm had revenue of $0.33 million during the quarter, compared to the consensus estimate of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 28.61% and a negative net margin of 16,648.93%.
Several research firms have recently issued reports on AUPH. HC Wainwright lowered their target price on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, May 18th. Vetr lowered shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating and set a $6.64 target price for the company. in a report on Wednesday. BidaskClub lowered shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Tuesday, August 15th. Finally, Cantor Fitzgerald set a $14.00 price objective on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $9.71.
Shares of Aurinia Pharmaceuticals (AUPH) opened at 6.74 on Friday. The stock’s market capitalization is $562.69 million. The stock has a 50 day moving average price of $6.23 and a 200 day moving average price of $6.56. Aurinia Pharmaceuticals has a 52 week low of $1.97 and a 52 week high of $10.54.
A number of large investors have recently bought and sold shares of AUPH. Bank of New York Mellon Corp bought a new stake in Aurinia Pharmaceuticals in the 1st quarter worth approximately $595,000. TD Asset Management Inc. bought a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter valued at $241,000. Quantbot Technologies LP bought a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter valued at $275,000. NEA Management Company LLC grew its position in shares of Aurinia Pharmaceuticals by 18.2% during the 1st quarter. NEA Management Company LLC now owns 4,808,483 shares of the biotechnology company’s stock valued at $35,294,000 after acquiring an additional 740,740 shares during the period. Finally, Credit Agricole S A bought a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter valued at $1,393,000. 27.83% of the stock is owned by institutional investors and hedge funds.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.